prikaz prve stranice dokumenta Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients – A retrospective cohort study on 5392 patients from a tertiary centre
  Preuzmi
PDF 1.52 MB
Znanstveni rad - Izvorni znanstveni rad
Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients – A retrospective cohort study on 5392 patients from a tertiary centre
International Journal of Cardiology, 372 (2023); 144-149. https://doi.org/10.1016/j.ijcard.2022.11.051
Bistrović, Petra; Sabljic, Anica; Kovačević, Ivona; Čikara, Tomislav; Kereš, Tatjana; Lucijanić, Tomo; Mitrović, Joško; Delić-Brkljačić, Diana; Manola, Šime; Lucijanić, Marko

Citirajte ovaj rad

Bistrović, P., Sabljic, A., Kovačević, I., Čikara, T., Kereš, T., Lucijanić, T. ... Lucijanić, M. (2023). Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients – A retrospective cohort study on 5392 patients from a tertiary centre. International Journal of Cardiology, 372., 144-149. doi: 10.1016/j.ijcard.2022.11.051

Bistrović, Petra, et al. "Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients – A retrospective cohort study on 5392 patients from a tertiary centre." International Journal of Cardiology, vol. 372, 2023, str. 144-149. https://doi.org/10.1016/j.ijcard.2022.11.051

Bistrović, Petra, Anica Sabljic, Ivona Kovačević, Tomislav Čikara, Tatjana Kereš, Tomo Lucijanić, Joško Mitrović, Diana Delić Brkljačić, Šime Manola i Marko Lucijanić. "Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients – A retrospective cohort study on 5392 patients from a tertiary centre." International Journal of Cardiology 372 (2023): 144-149. https://doi.org/10.1016/j.ijcard.2022.11.051

Bistrović, P., et al. (2023) 'Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients – A retrospective cohort study on 5392 patients from a tertiary centre', International Journal of Cardiology, 372, str. 144-149. doi: 10.1016/j.ijcard.2022.11.051

Bistrović P, Sabljic A, Kovačević I, Čikara T, Kereš T, Lucijanić T, i sur.. Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients – A retrospective cohort study on 5392 patients from a tertiary centre. International Journal of Cardiology [Internet]. 01.02.2023. [pristupljeno 01.12.2024.];372:144-149. doi: 10.1016/j.ijcard.2022.11.051

P. Bistrović, et al., "Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients – A retrospective cohort study on 5392 patients from a tertiary centre", International Journal of Cardiology, vol. 372, str. 144-149, Veljača 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:310444. [Citirano: 01.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:310444
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients – A retrospective cohort study on 5392 patients from a tertiary centre
AutorPetra Bistrović
AutorAnica Sabljic
AutorIvona Kovačević
AutorTomislav Čikara
AutorTatjana Kereš
AutorTomo Lucijanić
AutorJoško Mitrović
AutorDiana Delić-Brkljačić
AutorŠime Manola
AutorMarko Lucijanić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Introduction: There are conflicting data on prior oral-anticoagulant (OAC) use and outcomes of hospitalized COVID-19 patients. Due to uncertainties regarding associated risks with the prior OAC use, we have investigated this issue in a large cohort of hospitalized COVID-19 patients from our institution. Methods: We have retrospectively evaluated a total of 5392 consecutive COVID-19 patients hospitalized in our tertiary center institution in period 3/2020 to 6/2021. Majority of patients received low-molecular-weight-heparin thromboprophylaxis and corticosteroids during hospitalization. Patients' characteristics and clinical outcomes were documented as a part of a hospital registry project and were evaluated according to the prior non-OAC, warfarin and direct oral anticoagulants (DOAC) use. Results: Median age was 72 years, median Charlson comorbidity index (CCI) was 4 points. There were 56.2% male patients. Majority of patients had severe (70.5%) or critical (15.8%) COVID-19 on admission. A total of 84.8% patients did not receive prior OAC, 9% were previously anticoagulated with warfarin and 6.2% were previously anticoagulated with DOACs. In the multivariate regression analyses, prior warfarin use was associated increased in-hospital mortality (OR 1.24, P = 0.048) independently of older age (OR 2.12, P < 0.001), male sex (OR 1.27, P < 0.001), higher CCI (OR 1.26, P < 0.001) and severe or critical COVID-19 on admission (OR 22.66, P < 0.001). Prior DOAC use was associated with higher occurrence of major bleeding (OR 1.72, P = 0.045) independently of higher CCI (OR 1.08, P = 0.017). Conclusion: Prior OAC use could be associated with worse clinical outcomes during COVID-19 hospitalization. These phenomena might be OAC type specific and persist after multivariate adjustments.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaInternational Journal of Cardiology
Brojčani podacivol. 372, str. 144-149
p-ISSN0167-5273
DOIhttps://doi.org/10.1016/j.ijcard.2022.11.051
URN:NBNurn:nbn:hr:105:310444
Datum objave publikacije2023-02-01
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S0167527322017387
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2023-05-18 10:31:32